What dose was used in the tesamorelin trials?

The Phase 3 approval trials in HIV-associated lipodystrophy (Falutz et al. 2007) used tesamorelin as a once-daily subcutaneous injection, and the studied, subsequently approved dose is stated in the FDA prescribing information for Egrifta. That is the only dosing established in controlled human trials. PepVise points to the label as the primary source rather than restating a number that could be read as instruction.

Does the trial dose apply to off-label use?

No. The studied and approved dose is for a narrow indication, reducing visceral abdominal fat in HIV patients with lipodystrophy. There is no equivalently evidenced dose for the general fat-loss or anti-aging use circulating online in people without that indication. Applying a trial dose to a different population is off-label inference, not an established protocol.

Why does tesamorelin dosing involve IGF-1 monitoring?

Because tesamorelin raises growth hormone and therefore IGF-1, the label requires IGF-1 monitoring. The approved regimen is a dose plus surveillance inside a prescriber relationship, not a number in isolation. A dose stripped of that monitoring framework is not the regimen the trials validated.

How long was tesamorelin dosed in the studies?

The pivotal trials measured visceral-fat reduction over about 26 weeks, with partial regain after stopping (Falutz et al. 2010; Stanley et al. 2014). The effect is real, reversible, and time-limited in the studied population. The trials do not establish a safe long-term schedule for indefinite use.

Why does PepVise not give a specific tesamorelin dose?

Because tesamorelin is a prescription drug whose trial-based dose is in the label, and a dose from a website is not a substitute for a prescription from a licensed physician. We describe what the studies reported and point to our tesamorelin profile for the full context.

Explainer· Compounds

Tesamorelin dosage, what the studies report

By The PepVise Editorial Team · Reviewed June 29, 2026 · 11 min read

What the approval trials and the FDA label report about tesamorelin dosage, why the studied dose differs from the off-label use circulating online, and why PepVise does not prescribe a dose.

Mechanism explainers on PepVise aim for textbook-level clarity without the textbook's refusal to commit to a reading.

Frequently asked

What readers ask us next.

What dose was used in the tesamorelin trials?: The Phase 3 approval trials in HIV-associated lipodystrophy (Falutz et al. 2007) used tesamorelin as a once-daily subcutaneous injection, and the studied, subsequently approved dose is stated in the FDA prescribing information for Egrifta. That is the only dosing established in controlled human trials. PepVise points to the label as the primary source rather than restating a number that could be read as instruction.
Does the trial dose apply to off-label use?: No. The studied and approved dose is for a narrow indication, reducing visceral abdominal fat in HIV patients with lipodystrophy. There is no equivalently evidenced dose for the general fat-loss or anti-aging use circulating online in people without that indication. Applying a trial dose to a different population is off-label inference, not an established protocol.
Why does tesamorelin dosing involve IGF-1 monitoring?: Because tesamorelin raises growth hormone and therefore IGF-1, the label requires IGF-1 monitoring. The approved regimen is a dose plus surveillance inside a prescriber relationship, not a number in isolation. A dose stripped of that monitoring framework is not the regimen the trials validated.
How long was tesamorelin dosed in the studies?: The pivotal trials measured visceral-fat reduction over about 26 weeks, with partial regain after stopping (Falutz et al. 2010; Stanley et al. 2014). The effect is real, reversible, and time-limited in the studied population. The trials do not establish a safe long-term schedule for indefinite use.
Why does PepVise not give a specific tesamorelin dose?: Because tesamorelin is a prescription drug whose trial-based dose is in the label, and a dose from a website is not a substitute for a prescription from a licensed physician. We describe what the studies reported and point to our tesamorelin profile for the full context.

The sources

References cited on this page.

PubMed, ClinicalTrials.gov, and FDA documents only. Secondary sources appear when needed to characterize public discourse, never as a source for a clinical claim.

The masthead

About The Pepvise Editorial Team

The Pepvise Editorial Team is a small group of researchers and science writers reading the peer-reviewed peptide literature and translating it into calm, cited analysis. We do not sell peptides, recommend peptides, or tell readers what to administer. We describe what has been measured, by whom, at what scale, with what effect size.

Compound reviews are signed off by Dr. Priya Narang, MD, MPH (endocrinologist) and Dr. Marcus Haley, PharmD, BCPS (board-certified clinical pharmacist). Both hold verifiable state-board licenses and have signed editorial-independence letters with us. See the full editorial board →

Adjacent in the literature.

Compounds · Compound profile

BPC-157, What the Evidence Shows

Evidence Ledger for BPC-157: 50+ preclinical studies, 1 human pilot (Chang 2014, n=12), 1 active Phase trial, FDA removed from 503A list in 2023.

16 min read

Compounds · Compound profile

TB-500, The Field Guide

TB-500 vs Thymosin Beta-4 (same compound), mechanism, the preclinical tendon and recovery literature, and where the human data is thin.

14 min read

Compounds · Compound profile

GHK-Cu, Evidence and Hype

Copper peptide signaling, the topical RCT evidence for hair and skin, and the gap between topical and injectable claims.

13 min read

Get the 2026 Peptide Evidence Ledger.

A 12-page PDF summary of where 10 major compounds sit, Preclinical / Human pilot / Phase trial / FDA status. Updated quarterly. Free.

By subscribing, you agree to our Privacy Policy. One calm, cited email a week. Unsubscribe anytime.